Target Audience: This activity has been designed to meet the educational needs of rheumatologists, physician assistants, and nurse practitioners involved in the care of patients with rheumatoid arthritis.

Learning Objectives: After the completion of this activity, participants should be able to:

Identify those most at risk for developing RA

Outline the strategy for the optimal use of methotrexate in treating patients with RA

Discuss the role of practice metrics and treat-to-target in RA care

Physician Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of Purdue University College of Pharmacy and Focus Medical Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: Purdue University College of Pharmacy designates this enduring activity for a maximum of
0.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement: All faculty and staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

All additional planning committee members, reviewers and Focus Medical Communications and Purdue University College of Pharmacy staff have no relationships to disclose.

Dr. Cush has served as a consultant for AbbVie Inc., Amgen, BMS, Celgene, Genentech, Janssen, Pfizer and UCB. He has also been a clinical investigator for Amgen, Celgene, CORRONA, Genentech, Novartis, Pfizer and UCB.